Cyprotex (LSE:CRX) Other Long-Term Liabilities : £0.13 Mil (As of Jun. 2016)

View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Other Long-Term Liabilities?

Cyprotex's other long-term liabilities for the quarter that ended in Jun. 2016 was £0.13 Mil.

Cyprotex's quarterly other long-term liabilities declined from Jun. 2015 (£0.18 Mil) to Dec. 2015 (£0.13 Mil) and declined from Dec. 2015 (£0.13 Mil) to Jun. 2016 (£0.13 Mil).

Cyprotex's annual other long-term liabilities declined from Dec. 2013 (£1.75 Mil) to Dec. 2014 (£1.55 Mil) and declined from Dec. 2014 (£1.55 Mil) to Dec. 2015 (£0.13 Mil).

Cyprotex Other Long-Term Liabilities Historical Data

The historical data trend for Cyprotex's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Other Long-Term Liabilities Chart

Cyprotex Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Other Long-Term Liabilities

Get a 7-Day Free Trial

Cyprotex Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Cyprotex Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Cyprotex Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Cyprotex's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyprotex (LSE:CRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cyprotex.com

Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines